ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Blood-based biomarkers and early diagnosis of Alzheimer's disease.Neural regeneration research · 2026Article
- Plasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer's dementia in a real-world memory clinic population.Frontiers in aging neuroscience · 2026Article
- The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer's Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression.Molecular neurobiology · 2025Review
- Predicting brain amyloid load with digital and blood-based biomarkers.Alzheimer's research & therapy · 2025Article
- Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins.Bioanalysis · 2025Review
- Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease and Other Dementias: A Center-Based Study.International journal of molecular sciences · 2025Article
- Platelets mirror changes in the frontal lobe antioxidant system in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study.The journal of prevention of Alzheimer's disease · 2025Observational
- Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated LumipulseFluids and barriers of the CNS · 2025Article
- Validation of the robustness of blood-based biomarkers for predicting amyloid-β positivity in Chinese populations.Frontiers in aging neuroscience · 2025Article
- Independent validation of the PrecivityAD2™ blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment.NPJ dementia · 2025Article
- Analytical and clinical performance of eight SimoaAlzheimer's research & therapy · 2024Article
- Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications.Neurology and therapy · 2024Review
- Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia.Alzheimer's research & therapy · 2024Article
- Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
introductionThis study evaluated the performance of the Lumipulse plasma beta-amyloid (Aβ) 42/40 and pTau181 compared to other assays to detect an abnormal amyloid-positron emission tomography (PET).
methodsPlasma samples from cognitively unimpaired (
resultsLumipulse and IP-MS Aβ42/40 exhibited the highest diagnostic accuracy for detecting an abnormal amyloid-PET (areas under the curve [AUCs] of 0.81 and 0.84, respectively). The Lumipulse and Simoa pTau181 assays exhibited lower performance (AUCs of 0.74 and 0.72, respectively). The Simoa Aβ42/40 assay demonstrated the lowest diagnostic accuracy (AUC 0.57). Combining Aβ42/40 and pTau181 did not significantly improve performance over Aβ42/40 alone for Lumipulse (AUC 0.83) or over pTau181 alone for Simoa (AUC 0.71). DISCUSSION: The Lumipulse Aβ42/40 assay showed similar performance to the IP-MS Aβ42/40 assay for detection of an abnormal amyloid-PET; and both assays performed better than the two p-tau181 immunoassays. The Simoa Aβ42/Aβ40 assay was the least accurate at predicting an abnormal amyloid-PET status. Highlights: Lumipulse plasma Aβ42/Aβ40 AUC for abnormal amyloid-PET detection was 0.81.This performance was comparable to previously reported IP-MS and higher than Simoa.Performance of Alzheimer's disease blood biomarkers varies between assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.